Client situation: An immunology early-pipeline team had an asset ready for Phase 2 and needed to make an indication choice amid uncertain standard-of-care shifts, access tightening, and competitor catalysts.

Eradigm’s approach:

• Aligned on Phase 2 success criteria and key uncertainties upfront
• Built three future-state scenarios linked to standard of care, competitive pipelines and market access evolution
• Pressure-tested assumptions through cross-functional working sessions
• Defined signposts to track as evidence evolved

What the client achieved:

• Facilitated alignment: structured working sessions surfaced assumptions and landed cross-functional decisions fast
• Decision-linked scenarios: built around real strategic choices, not abstract narratives
• Actionable next steps: implications translated into clear actions and trigger-based updates as the market moved

Client voice: “Eradigm didn’t just outline possible futures — they helped us align cross-functionally on what we would actually do in each one.” — New Product Planning Lead, global immunology team